Clinical trial
Lipiodol Combined With Microspheres TACE for Unresectable HCC
NCT05875558 is registered in ClinicalTrials.gov with Shanghai Zhongshan Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Lipiodol Combined With Microspheres TACE for Unresectable HCC
- Lead sponsor
- Shanghai Zhongshan Hospital
- Phase
- Not applicable
- Overall status
- Unknown status
- Start date
- July 1, 2022
- Completion date
- July 1, 2024
- Enrollment
- 40 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
hepatocellular carcinoma